Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 58Small Cell Lung Carcinoma 22Carcinoma, Hepatocellular 17Neoplasms 15Lung Neoplasms 14Biliary Tract Neoplasms 12Neoplasm Metastasis 11Breast Neoplasms 11Recurrence 10Squamous Cell Carcinoma of Head and Neck 9Melanoma 9Carcinoma 9Advanced Solid Tumors 8Triple Negative Breast Neoplasms 7Stomach Neoplasms 7Lymphoma, Large B-Cell, Diffuse 7Liver Neoplasms 7Head and Neck Neoplasms 7Urinary Bladder Neoplasms 6Ovarian Neoplasms 6Carcinoma, Renal Cell 6Prostatic Neoplasms 5Lymphoma 5Uterine Cervical Neoplasms 4Neoplasms by Site 4Multiple Myeloma 4Lymphoma, Follicular 4Colorectal Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pancreatic Neoplasms 3

Interventions

Gemcitabine 4Cisplatin 4Carboplatin 3pembrolizumab 2erdafitinib 2vinflunine 1tremelimumab 1enfortumab vedotin 1durvalumab 1avelumab 1atezolizumab 1Tiragolumab 1Sunitinib 1Nivolumab 1Midazolam 1Metformin 1Ipilimumab 1Docetaxel 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Urothelial Cancer × durvalumab × Clear all
NCT02516241 2026-04-20

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

AstraZeneca

Phase 3 Active not recruiting
1,126 enrolled 52 charts
Genitourinary

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡